THERAPY DOSSIER · th-4c2881b27894

DHA-loaded polylactic acid core-shell nanofiber membrane (PLA/DHA CSNM)

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32987768 ↗2020Reported benefit

Docosahexaenoic Acid-Loaded Polylactic Acid Core-Shell Nanofiber Membranes for Regenerative Medicine after Spinal Cord Injury: In Vitro and In Vivo Study

RatSpinal cord injuryHemisection / partialSprague-DawleyFemaleLocal implantation over lesion site (in vivo); co-culture/diffusion (in vitro)Membrane DHA loading 6.23 ± 0.43 μg/mg CSNM (core solution…Implanted at time of SCI surgery

Model: Cervical lateral hemisection spinal cord injury (C4-C5)

PLA/DHA CSNM significantly improved neurological function recovery (grid exploration and cylinder tests) from 1-2 weeks post-SCI compared with PLA-only and untreated controls, reduced neuronal loss, and increased serotonergic nerve sprouting caudal to the lesion; in vitro, sustained DHA release inc…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…